• Title of article

    An Adjuvant Capsule in the Treatment of Pemphigus Vulgaris: A Novel Hypothesis

  • Author/Authors

    Jowkar, Farideh Molecular Dermatology Research Center and Department of Dermatology - Shiraz University of Medical Sciences, Shiraz , Saki, Nasrin Molecular Dermatology Research Center and Department of Dermatology - Shiraz University of Medical Sciences, Shiraz - Student Research Committee - Shiraz University of Medical Sciences , Kardeh, Sina Molecular Dermatology Research Center and Department of Dermatology - Shiraz University of Medical Sciences, Shiraz - Student Research Committee - Shiraz University of Medical Sciences

  • Pages
    2
  • From page
    200
  • To page
    201
  • Abstract
    Pemphigus vulgaris (PV) is one of the most common and studied autoimmune disorders of skin. The knock down of desmogleins in the skin by IgG antibodies will eventually leads to mucocutaneous problems in both genders. Targeting the cardinal molecules involved in the pathways of immune response is the main goal of given therapy. With regard to the side effects of long term use of immunosuppressive treatments, patients may use various adjuvant drug combinations. Sulfasalazine (SSZ) and Pentoxifylline (PTX) are two low-cost anti-TNF medications that can halt the acantholysis in PV. Tetracycline is an effective antibiotic with immunomdulatory properties on down-regulation of pro-inflammatory molecules such as NO, IL-1β. Moreover, the anti-inflammatory effects of Omega-3 take this supplement into account as a potential addition to anti-PV armamentarium. Thus, this complex could be utilized as a safe and effective adjuvant capsule against PV.
  • Keywords
    Pemphigus Vulgaris , Adjuvant , Skin , Hypothesis
  • Journal title
    Astroparticle Physics
  • Serial Year
    2014
  • Record number

    2417937